FDA Revamps Guidance on Protocols for CMC Changes

Drug Industry Daily
The FDA has a slate of new recommendations companies should follow when submitting a comparability protocol assessing changes to the chemistry, manufacturing or controls of a drug or biologic after the agency has approved its production process.

To View This Article:


Subscribe To Drug Industry Daily